Apple Eyes AI Leadership in China by Partnering with Tencent and ByteDance for iPhone Integration 
Starbucks Baristas Kick Off Strikes in LA, Chicago, and Seattle as Holiday Pressure Mounts 
BC.GAME Enters Online Poker Market with BCPoker Launch Featuring Three Classic Variants 
US Targets Huawei Ties in TSMC AI Chip Scandal Sparking Fresh Tech Showdown 
Honda, Nissan Discuss Factory Sharing Moves to Counter Trump’s Trade Shifts and Expand Global Reach 
Nintendo Switch 2 Dock Leak Hints at Faster Performance but 4K Output Reportedly Capped at 30 FPS 
Canada's Response to Trump Tariffs Fuels Major Concern for Japan's Komatsu in Key Export Markets 
Goldman Sachs Warns of Government Shutdown Risk as House Blocks Spending Package, Deadline Nears 
Soaring EV Sales Spark Scramble for Lithium and Graphite as 2030 Supply Pinch Looms 
How To Prepare for Global Economic Shifts in 2025? 
Starbucks Union Strike Expands Nationwide as Baristas Demand Higher Wages, Better Schedules, and Fair Staffing 
The Crypto Market is Thrown into Chaos as XRP Plummets 12% & $1 Trillion is Wiped Out 
Biden’s $300M Contracts to Reuters ‘Target Elon Musk’ as Federal Agencies Investigate His Companies: Report 
Elon Musk Tells Users to ‘Stop Using Hashtags’ on X as Platform Moves Away From Trends 
Why Scottish salmon’s rebrand may end up harming the integrity of a top export and hurting producers 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
